key: cord-0786508-rxlrow84
authors: Geskin, Larisa J; Garcia-Saleem, Tiffany; Akilov, Oleg E; Enz, Paula; Guenova, Emmanuella; Ortiz-Romero, Pablo L; Papadavid, Evangelia; Quaglino, Pietro; Rozati, Sima; Stonesifer, Connor; Burns, Austin; Khaleel, Alexandra; Scarisbrick, Julia J
title: Epi-O-02 International Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of CTCL outcomes during COVID-19
date: 2021-10-31
journal: European Journal of Cancer
DOI: 10.1016/s0959-8049(21)00685-7
sha: 9cedf235effd6252af05f523498e9c7ad19a0253
doc_id: 786508
cord_uid: rxlrow84

At the onset of the COVID-19 pandemic, the United States Cutaneous Lymphoma Consortium (USCLC) and the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Task Force (EORTC-CLTF) developed emergency guidelines for the management of patients with cutaneous lymphomas (CLs) during the pandemic. These emergency protocols were intended to ensure patient safety and called for dose modifications, treatment delays and treatment interruptions as necessary to minimize exposure risks to COVID-19. Because there are no established maintenance protocols for CLs, the impact of such delays or interruptions on disease outcomes was not known. The ISCL created an International Cutaneous Lymphomas Pandemic Section (ICLYPS) to collect data from the institutions around the world to assess the impact of these changes on patients’ outcomes and to determine if these measures were effective in preventing infection. We summarize the outcomes from a preliminary cohort of patients from Brazil, Greece, Italy, Spain, Switzerland, the UK and the US. Actively managed patients with an established diagnosis of CL from March to October 2020 were included according to the Institutional Protection of Human Subjects guidelines at the respective centers. We included 149 patients in this retrospective review. The average age was 61.88 years (range: 22–95). 2 patients (1.3%) had diagnoses of CD30+ lymphoproliferative disorders (LyP and pcALCL), 112 (75.2%) had mycosis fungoides (MF), and 35 (23.5%) had Sézary syndrome (SS). 77 patients (68.7%) had stages IA–IIA MF, 23 (20.5%) had Stage IIB MF, 6 (5.4%) had stage III MF, and 41 (27.5%) had Stage IV disease, of which 6 had Stage IV MF (5.4%) and 35 had SS (23.5%). Treatment was delayed for more than half (53.0%) of the patients for a mean of 3.2 months (range: 10 days to 10 months). Treatment delay was associated with a significant risk of disease relapse or progression across all stages (65.8% vs 32.9%, p<0.00001). During follow up, 6 patients (4%) died due to disease progression, including 3 patients with Stage IIB MF, one with Stage IVB MF, and two with SS. Twenty-eight patients (18.8%) had a confirmed COVID-19 infection during the capture period. Two of these cases were definitive hospital-acquired infections following prolonged hospital admission, while the remaining contracted the virus through community exposures. There were no outpatient office-acquired infections. Three of the 26 patients who contracted COVID-19 died of the infection (2 SS and 1 LyP, mean age: 80, range: 66–89). The ICLYPS analysis has revealed that treatment interruptions and delays during the COVID-19 pandemic resulted in significantly worse outcomes in patients with CLs as compared to those who did not experience treatment interruptions. No outpatient office-acquired infections were reported in this extensive review, and patients with CLs who developed COVID-19 did not do worse than expected according to their risk factors. Effective safety measures and protocols can prevent transmission of COVID-19 at physicians’ offices. Interruption of therapy leads to negative clinical outcomes and should be avoided, especially in the setting of advanced disease, as the risk of contracting COVID-19 in the outpatient setting did not outweigh the risk of morbidity and mortality due to disease progression. Ensuring continuity of treatment and maintenance therapy appears to be critical to avoiding life-threatening disease progression.

of non-Hodgkin lymphomas that diff er greatly in clinical presentation and prognosis. Mycosis fungoides (MF) is the most frequent subtype. Sézary syndrome (SS) is less prevalent but has a much more unfavourable prognosis. Previous studies have shown that the incidence of CTCL has tripled between 1970 and 2000 but since then has stabilized. However, data on the incidence of MF and SS in the Netherlands have never been published. The aim of the present study was to estimate the changes in incidence of newly diagnosed MF and SS in the Netherlands over the last 20 years. Annual incidence rates were retrieved from the Dutch Cutaneous Lymphoma Registry (DCLR) between January 2000 and December 2019. In all cases, the diagnosis was based on the clinicopathological criteria of the World Health Organization European Organisation for Research and Treatment of Cancer classification and confirmed by an expert panel of dermatologists and pathologists at a periodical meeting of the Dutch Cutaneous Lymphoma Working Group. We calculated the number of registered patients with MF and SS per 100 000 persons, corrected for the size of the Dutch population. 1044 patients with MF, including 238 patients with folliculotropic MF (FMF), and 93 patients with SS were included. In 2000, the corrected number of cases of MF was 0.19 per 100 000 persons, while this was 0.35 per 100 000 in 2010 and 0.46 per 100 000 persons in 2019. This means that a 2.42-fold increase, corrected for Dutch population growth, was seen between 2000 and 2019 for the incidence of MF in the Netherlands. In 2000, 2010 and 2019 the corrected incidences for SS were 0.013, 0.018 and 0.075 per 100 000 persons, respectively. The overall increase for SS was 6.0-fold corrected for the Dutch population between 2000 and 2019. In summary, a significant increase of patients with classical MF, FMF and SS included in the DCLR was seen over the past 20 years. In contrast to previous studies that suggest a stabilization since 2000, this study shows that the incidence of patients with MF and SS in the Netherlands increased 2.42-fold over the past two decades.

Keywords: Cutaneous T-cell lymphoma, mycosis fungoides, folliculotropic mycosis fungoides, Sézary syndrome, incidence, epidemiology At the onset of the COVID-19 pandemic, the United States Cutaneous Lymphoma Consortium (USCLC) and the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Task Force (EORTC-CLTF) developed emergency guidelines for the management of patients with cutaneous lymphomas (CLs) during the pandemic. These emergency protocols were intended to ensure patient safety and called for dose modifi cations, treatment delays and treatment interruptions as necessary to minimize exposure risks to COVID-19. Because there are no established maintenance protocols for CLs, the impact of such delays or interruptions on disease outcomes was not known. The ISCL created an International Cutaneous Lymphomas Pandemic Section (ICLYPS) to collect data from the institutions around the world to assess the impact of these changes on patients' outcomes and to determine if these measures were eff ective in preventing infection. We summarize the outcomes from a preliminary cohort of patients from Brazil, Greece, Italy, Spain, Switzerland, the UK and the US. Actively managed patients with an established diagnosis of CL from March to October 2020 were included according to the Institutional Protection of Human Subjects guidelines at the respective centers. We included 149 patients in this retrospective review. The average age was 61.88 years (range: 22-95). 2 patients (1.3%) had diagnoses of CD30+ lymphoproliferative disorders (LyP and pcALCL), 112 (75.2%) had mycosis fungoides (MF), and 35 (23.5%) had Sézary syndrome (SS). 77 patients (68.7%) had stages IA-IIA MF, 23 (20.5%) had Stage IIB MF, 6 (5.4%) had stage III MF, and 41 (27.5%) had Stage IV disease, of which 6 had Stage IV MF (5.4%) and 35 had SS (23.5%). Treatment was delayed for more than half (53.0%) of the patients for a mean of 3.2 months (range: 10 days to 10 months). Treatment delay was associated with a signifi cant risk of disease relapse or progression across all stages (65.8% vs 32.9%, p<0.00001). During follow up, 6 patients (4%) died due to disease progression, including 3 patients with Stage IIB MF, one with Stage IVB MF, and two with SS. Twenty-eight patients (18.8%) had a confi rmed COVID-19 infection during the capture period. Two of these cases were defi nitive hospital-acquired infections following prolonged hospital admission, while the remaining contracted the virus through community exposures. There were no outpatient offi ce-acquired infections. Three of the 26 patients who contracted COVID-19 died of the infection (2 SS and 1 LyP, mean age: 80, range: 66-89). The ICLYPS analysis has revealed that treatment interrup-tions and delays during the COVID-19 pandemic resulted in signifi cantly worse outcomes in patients with CLs as compared to those who did not experience treatment interruptions. No outpatient offi ce-acquired infections were reported in this extensive review, and patients with CLs who developed COVID-19 did not do worse than expected according to their risk factors. Eff ective safety measures and protocols can prevent transmission of COVID-19 at physicians' offi ces. Interruption of therapy leads to negative clinical outcomes and should be avoided, especially in the setting of advanced disease, as the risk of contracting COVID-19 in the outpatient setting did not outweigh the risk of morbidity and mortality due to disease progression. Ensuring continuity of treatment and maintenance therapy appears to be critical to avoiding life-threatening disease progression.

Keywords Primary cutaneous lymphoma (CL) form a heterogenous group of non-Hodgkin lymphoma (NHL). The CL are divided into T cell lymphoma (CTCL), these form the majority of CL with 73%, followed by B cell lymphoma (CBCL) with 22% and the rare lymphoma build 5% based on the current WHO-classifi cation. There are only few studies, which treated the CL topic and its incidence, prevalence and survival in Germany. The last study has been published in the year 2007 including 998 patients from 26 diff erent centers. However, recent studies from other national registries show a slight increasing tendency of incidence and prevalence of CL. Therefore, the underlying study investigated aged-standardized incidence rates and 5-year survival of CL for the time period 2008-2017 with data of the population-based cancer registry (LKR) of North Rhine-Westphalia, the largest Federal State of Germany (18 million inhabitants). Overall, 2826 patients with CL were registered in the period of 2008 till 2017 of the cancer registry. The LKR is a reporting point of all forms of cancer, based on an obligated report for all pathologists and dermatopathologists since 2005. The data is allocated as followed 1743 male (61.7%) and 1083 female (38.3%) with a rate of male>female (1.6:1). The present work shows based on the registration of 2826 patients the dominance of cutaneous T-cell-lymphoma (68%) in comparison to cutaneous B-cell-Lymphoma (24.9%), however we also divided the primary cutaneous B cell lymphoma (CBCL) in one overall category (n=905) and three subtypes (n=705): follicular B cell lymphoma (C82), diff use large B cell lymphoma (C83.3) and marginal zone lymphoma; C88.40), with the following distribution 37.7%, 30.2%, 32.1%. The age-standardized incidence rates (per 100 000 person-years) of cutaneous lymphoma were 1,5 and 0,8 among men and women. Five-year absolute survival was 79.1% in MF, and 77.3% in all CBCL and 88.2% in marginal zone lymphoma, 89.6% in follicular lymphoma and 49.6% in diff use large B cell lymphoma, respectively. Overall, there is a stable incidence in CTCL and a slightly increasing incidence of CBCL (0.14 in 2008 to 0.34 in 2017). This progression in CBCL may be due to higher awareness and clear substratifi cation based on the recent classifi cations.

Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG)

Incidence of mycosis fungoides and Sézary syndrome in the Netherlands between 2000 and 2020

Keywords: MF, mycosis fungoides, Sézary syndrome, CL, cutaneous lymphoma, CTCL, cutaneous T-cell lymphoma, CBCL, cutaneous B-cell lymphoma

The impact of pregnancy on cutaneous T-cell lymphoma (CTCL) and lymphoproliferative disorders (LPDs) is mostly unexplored territory limited to case reports and series. For patients considering pregnancy, the lack of available data and limited pregnancy-safe treatment options can be distressing. The objective of this retrospective study was to explore relationships between CTCL/LPD and pregnancy. From our cutaneous lymphoma clinic, we identifi ed 37 patients with a documented history of pregnancy (n=77 pregnancies). After excluding pregnancies prior to the onset of CTCL/LPD symptoms (n=40), 37 pregnancies in 22 patients were included. Demographics and medical history were extracted from patient records, then semi-structured interviews were conducted to inquire about skin changes during pregnancy. Diagnoses included mycosis fungoides (MF) (16/22, 72.7%), lymphomatoid papulosis (LyP) (4/22, 18.2%), pleomorphic small/medium T-cell LPD (1/22, 4.6%), and subcutaneous panniculitis-like T-cell lymphoma (1/22, 4.6%) (SPTCL). All patients had early-stage disease. Overall, most patients reported their skin condition worsened or fl ared (21/37, 56.8%) during pregnancy. 12 patients (32.4%) reported stable disease, and 3 patients reported improvement (4/37, 10.8%). No patients developed extracutaneous involvement during pregnancy or breastfeeding. Aside from prematurity, no fetal complications were reported. One patient had stable MF IA prior to her fi rst pregnancy but rapidly progressed to IB in the setting of interferon alfa-2b discontinuation, requiring preterm caesarean delivery and extensive radiotherapy (RT). She continued treatment throughout her second pregnancy with adequate disease control but developed new symptomatic plaques requiring further RT in the months following delivery. Flares were reported in 3 of 4 pregnant patients with LyP, none of whom were on systemic therapy directly before or during pregnancy. The patient with SPTCL was free of lesions during both of her pregnancies, with fl ares recurring 6 months postpartum. Four patients with MF experienced worsening of previously undiagnosed patches, two of whom were diagnosed 9 months postpartum. The remaining two patients were diagnosed several years after pregnancy. Treatment options for pregnant patients with CTCL/LPD are limited due to teratogenicity. For example, methotrexate, fi rst-line therapy for LyP, is an abortifacient with potential for causing fetal anomalies. Topical corticosteroids and phototherapy are safe throughout pregnancy, whereas treatments for advanced disease like bexarotene and acitretin are contraindicated. The overall contribution of pregnancy-induced immunosuppression cannot